Cite
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.
MLA
Haen, Sebastian, et al. “Uric Acid as a Novel Biomarker for Bone-Marrow Function and Incipient Hematopoietic Reconstitution after Aplasia in Patients with Hematologic Malignancies.” Journal of Cancer Research & Clinical Oncology, vol. 143, no. 5, May 2017, pp. 759–71. EBSCOhost, https://doi.org/10.1007/s00432-017-2348-z.
APA
Haen, S., Eyb, V., Mirza, N., Naumann, A., Peter, A., Löffler, M., Faul, C., Vogel, W., Bethge, W., Rammensee, H.-G., Kanz, L., & Heni, M. (2017). Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies. Journal of Cancer Research & Clinical Oncology, 143(5), 759–771. https://doi.org/10.1007/s00432-017-2348-z
Chicago
Haen, Sebastian, Vicky Eyb, Nora Mirza, Aline Naumann, Andreas Peter, Markus Löffler, Christoph Faul, et al. 2017. “Uric Acid as a Novel Biomarker for Bone-Marrow Function and Incipient Hematopoietic Reconstitution after Aplasia in Patients with Hematologic Malignancies.” Journal of Cancer Research & Clinical Oncology 143 (5): 759–71. doi:10.1007/s00432-017-2348-z.